Introduction
Methods
Sample recruitment
Data collection
Analysis
Data processing
Data analysis
Results
Patient demographics and clinical characteristics
Group 1 | Group 2 | Group 3 | |
---|---|---|---|
(n = 89) | (n = 108) | (n = 102) | |
Patient characteristics | |||
Mean (SD) age (years) | 55.0 (11.1) | 57.7 (10.6) | 55.3 (11.2) |
Ethnicitya (n, %) | |||
White British | 75 (84.3%) | 101 (93.5%) | 83 (81.4%) |
Other | 10 (11.2%) | 7 (6.5%) | 15 (14.7%) |
Educationb | |||
GCSE (or equivalent) or higher (n, %) | 66 (74.2%) | 81 (75.0%) | 81 (79.4%) |
No formal qualifications | 21 (23.6%) | 26 (24.1%) | 19 (19.6%) |
≥ 1 clinically significant comorbiditiesc, (n, %) | 11 (12.4%) | 10 (9.3%) | 15 (14.7%) |
Disease characteristics | |||
Tumour stage (n, %) | |||
Stage I | 20 (22.5%) | 25 (23.1%) | 0 (0.0%) |
Stage II | 54 (60.7%) | 53 (49.1%) | 0 (0.0%) |
Stage III | 14 (15.7%) | 29 (26.9%) | 0 (0.0%) |
Stage IV | 0 (0.0%) | 0 (0.0%) | 101 (99.0%) |
Not recorded | 1 (1.1%) | 0 (0.0%) | 1 (1.0%) |
Hormone receptor-positive (n, %) | |||
Yes | 64 (71.9%) | 84 (77.8%) | 74 (72.5%) |
No | 25 (28.1%) | 24 (22.2%) | 26 (25.5%) |
Not known | 0 (0.0%) | 0 (0.0%) | 2 (2.0%) |
Median (IQR) time since early BC diagnosis (months) | 9.0 (6.0) | 45.0 (32.0) (n = 103) | 79.5 (82.0) (n = 71) |
Median (IQR) time since metastatic BC diagnosis (months) | 30.0 (37.0) | ||
Type of metastatic BC diagnosis (n, %) | |||
De novo | – | – | 27 (26.5%) |
Relapsed | – | – | 75 (73.5%) |
Sites of metastatic BC disease (n, %) | |||
Non-visceral | – | – | 23 (22.5%) |
Visceral involvement | – | – | 77 (75.5%) |
Visceral involvement unknown | – | – | 2 (2.0%) |
No CNS involvement | – | – | 71 (69.6%) |
CNS involvement | – | – | 25 (24.5%) |
CNS involvement unknown | – | – | 6 (5.9%) |
Employment status and work productivity
Group 1 | Group 2 | Group 3 | Between-group differences | |
---|---|---|---|---|
p valued | ||||
Employment status (n, %) | ||||
Employed (full-time, part-time and self-employed) | 45 (50.6) | 55 (50.9)* | 28 (27.5)** | < 0.001 |
Not employeda | 41 (46.1) | 52 (48.1) | 69 (67.6) | |
Retired | 22 (24.7) | 39 (36.1) | 33 (32.4) | |
Unable to work | 7 (7.9) | 5 (4.6)** | 27 (26.5)** | |
Not statedb | 12 (13.5) | 8 (7.4) | 9 (8.8) | |
Unknown | 3 (3.4) | 1 (0.9) | 5 (4.9) | |
Part-time hours worked per week (mean, SD)c | 19.45 (6.04) (n = 20) | 22.94 (6.36) (n = 20) | 15.15 (7.44) (n = 13) | 0.006 |
Health-related quality of life
EQ-5D-5L
Group 1 | Group 2 | Group 3 | Between-group differences | |
---|---|---|---|---|
Fisher p value | ||||
Utility weighted by the England tariff | 0.809 (0.170) (n = 86) | 0.818 (0.181) (n = 108) | 0.695 (0.262) (n = 97) | < 0.001 |
Visual analogue scale | 72.74 (18.39) (n = 89) | 77.01 (17.53) (n = 108) | 65.82 (22.86) (n = 99) | < 0.001 |
FACT-B
Group 1 | Group 2 | Group 3 | Between-group differences | |
---|---|---|---|---|
Fisher p value | ||||
FACT-B subscales (mean, SD) | ||||
Physical wellbeing | 20.57 (5.93) (n = 86) | 22.63 (5.08) (n = 107) | 18.81 (6.89) (n = 101) | < 0.001 |
Social wellbeing | 23.62 (4.88) (n = 86) | 22.26 (5.23) (n = 108) | 20.65 (6.34) (n = 100) | 0.001 |
Emotional wellbeing | 18.13 (4.87) (n = 87) | 17.68 (4.87) (n = 107) | 15.19 (5.99) (n = 100) | < 0.001 |
Functional wellbeing | 18.69 (6.32) (n = 88) | 20.76 (5.52) (n = 108) | 16.43 (7.30) (n = 101) | < 0.001 |
Breast cancer-specific | 22.01 (7.00) (n = 86) | 22.38 (7.68) (n = 108) | 21.37 (6.96) (n = 101) | 0.602 |
FACT-B summary scores (mean, SD) | ||||
FACT-Ga | 80.89 (17.69) (n = 85) | 83.19 (16.80) (n = 106) | 71.07 (22.42) (n = 99) | < 0.001 |
FACT-B total | 102.93 (23.41) (n = 85) | 105.58 (23.00) (n = 106) | 92.24 (27.38) (n = 99) | < 0.001 |
Trial outcome indexb | 61.19 (16.95) (n = 86) | 65.74 (16.05) (n = 107) | 56.61 (18.14) (n = 101) | 0.001 |